Overview
QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea
Status:
Withdrawn
Withdrawn
Trial end date:
2012-12-01
2012-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study is to describe the quality of life of Korean patients with early relapsing-remitting multiple sclerosis during the initial 1 year of treatment with Betaferon with several validated questionnaires.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
BayerTreatments:
Interferon beta-1b
Interferon-beta
Interferons
Criteria
Inclusion Criteria:- Relapsing-remitting MS (RRMS) patients within the first two years after diagnosis
according to Poser or McDonald criteria, starting Betaferon treatment, including
patients switching from other DMDs
- Patients who signed informed consent form
Exclusion Criteria:
- Age lower than 18